# GPT-6 Astra / mol-r03

Original final answer, shared by both scoring rounds.

## Recommended next question

**Does the caspase-generated amino-terminal fragment of gasdermin D directly permeabilize a lipid bilayer—and, if so, does it form discrete pores rather than cause nonspecific membrane disruption?**

The highest-value next action is **controlled, purified-component membrane reconstitution**, followed by tests connecting any demonstrated membrane activity to cellular death. This directly addresses the gap left by the supplied genetic and fragment-expression evidence: whether gasdermin D is a membrane-damaging executor or acts through another cellular component.

**Everything below is a proposal, not a reported experiment or result.** The packet supplies no purified-protein membrane results and no author methods to reproduce.

## 1. Evidence-to-inference-to-conclusion chain

| Supplied evidence | Justified inference | What remains unresolved |
|---|---|---|
| Inflammatory caspases cleave gasdermin D. | Gasdermin D processing is connected to inflammatory caspase activity. | Cleavage does not itself identify the fragment’s physical action. |
| Genetic loss and fragment-expression experiments link processing to pyroptotic death. | Gasdermin D and its processing have a functional relationship to death in the tested cellular settings. | A cellular phenotype does not establish direct membrane action. |
| The amino-terminal portion carries cytotoxic activity. | The amino-terminal portion is the leading candidate for an execution-related activity. | It could damage membranes directly, activate another executor, or perturb another process that eventually injures membranes. |
| No subsequent purified-protein membrane experiments are supplied. | Direct membrane activity has not been established within this packet. | Membrane binding, pore formation, lipid requirements, and cofactor requirements remain open. |

**Present conclusion:** the amino-terminal fragment is linked to cytotoxicity, but its molecular execution mechanism is unresolved.

## 2. Competing mechanisms and discriminating predictions

| Mechanism | Predictions in a minimal membrane system | Important qualifications |
|---|---|---|
| **A. Direct pore formation.** The amino-terminal fragment binds and assembles in a bilayer to create aqueous pathways. | Purified fragment causes reproducible permeability without cellular proteins. Membrane association precedes or accompanies leakage. Electrical measurements and structural observations support membrane-spanning openings. | Lipid dependence is compatible with direct action. Oligomerization or ring-shaped particles alone do not establish pores. |
| **B. Direct, non-pore membrane destabilization.** The fragment disrupts packing, fragments membranes, or causes catastrophic rupture. | Protein-only reconstitution gives leakage, but it accompanies vesicle collapse, fragmentation, or loss of intact bilayers rather than sustained permeability through identifiable openings. | Transient defects can resemble pores in some assays. Leakage alone cannot distinguish A from B. |
| **C. Indirect execution.** The fragment activates or recruits a cellular component that causes membrane injury. | Validated fragment lacks activity in adequately tested protein-free membranes, while a defined cellular component restores injury in a fragment-dependent manner. | A negative reconstitution assay alone is insufficient: the relevant membrane composition or protein state may be missing. |
| **D. Cofactor-assisted direct action.** A cellular factor enables fragment binding, activation, or assembly, but the fragment contributes directly to the damaging structure. | A defined factor restores fragment-dependent permeability; subsequent localization, removal, or structural experiments distinguish an enabling factor from a separate executor. | Factor dependence does not automatically mean indirect execution. |

An additional possibility is **artifactual permeability from contaminants, aggregation, or excessive protein loading**. This must be excluded before assigning biological significance.

## 3. Ordered proposed research plan

### Step 1 — Establish prerequisites and freeze the experimental logic

**Unreported parameters requiring resolution:** gasdermin D species and sequence, caspase identity, cleavage boundaries, expression system, purification conditions, relevant cell model, membrane composition, and effective cellular fragment abundance.

Before confirmatory experiments:

1. Select one matched gasdermin D–caspase pair and document its identity.
2. Determine or verify cleavage boundaries experimentally; do not assume a residue number.
3. Define the actual amino- and carboxy-terminal products by intact mass and/or peptide mapping.
4. Establish a cellular benchmark in a tractable model: confirm cleavage and reproduce amino-terminal-fragment-associated cytotoxicity. This is a construct/reagent benchmark, **not evidence of direct membrane action**.
5. Record construct sequences, tags, tag-removal scars, expression hosts, purification history, storage, freeze–thaw exposure, and assay buffers.
6. Separate exploratory optimization from confirmatory testing. Freeze the primary formulation, dose, endpoint, exclusion criteria, statistical model, and decision thresholds before examining confirmatory outcomes.

If a cell benchmark cannot be established, reconstitution can proceed, but a negative result will have substantially weaker biological interpretability.

### Step 2 — Prepare an identity-controlled protein panel

Prepare:

- Full-length gasdermin D.
- The amino-terminal fragment with verified native boundaries.
- The complementary carboxy-terminal fragment.
- Caspase-cleaved full-length gasdermin D.
- Amino-terminal material isolated from that cleavage reaction, if recovery permits.
- Uncleaved full-length material subjected to matched incubation and handling.
- Caspase alone.
- A mock purification from the same expression host and purification workflow.

A cleavage-resistant full-length comparator is useful **only after** the cleavage site is established and its biochemical integrity is checked. Do not interpret a poorly folded cleavage-resistant construct as a specific cleavage control.

**Quality checks**

- Confirm identity, concentration, cleavage extent, purity, and soluble recovery.
- Measure aggregation and sample heterogeneity before and after assay incubation.
- Remove or quantify residual purification detergents and other membrane-active additives.
- Remove tags where feasible; otherwise compare tagged and tag-cleaved preparations.
- Measure residual caspase activity after cleavage-product isolation.
- Maintain matched final buffer composition across treatments.
- Report nominal protein concentration and any measurable loss to precipitation or vessel adsorption.

Use both separately expressed and cleavage-generated amino-terminal material where possible. Agreement reduces concern that activity arises from one construct or purification route.

**Contamination controls:** test caspase at the measured carryover level and at a conservative upper bound; test the corresponding mock-purification fractions. If a contaminant or processing reagent produces comparable leakage, attribution to gasdermin D must stop pending resolution.

### Step 3 — Build and qualify protein-free membranes

**Proposed starting conditions, not reported author methods:** prepare approximately 100-nm unilamellar vesicles and begin with a neutral, near-physiological buffer—for example, pH 7.4 with approximately 150 mM monovalent salt. Exact buffer constituents and temperature must be qualified for protein and vesicle stability.

Use a small, predeclared lipid panel:

1. A neutral phospholipid formulation.
2. The same base formulation containing an anionic phospholipid.
3. Corresponding formulations with and without cholesterol.
4. A formulation informed by measured lipid composition of the selected cellular model, if available.

No specific lipid preference is established by the packet. Avoid treating one arbitrarily chosen membrane as a universal test.

For every vesicle preparation:

- Record lipid identities, molar fractions, total lipid concentration, size distribution, and preparation date.
- Check gross morphology and membrane integrity.
- Remove unencapsulated reporter.
- Measure baseline reporter retention over the full assay period.
- Match internal and external osmotic conditions.
- Verify that all final assay buffers and caspase carryover conditions preserve vesicle integrity.

Standard symmetric vesicles do not reproduce cellular leaflet asymmetry. A negative result may therefore warrant an asymmetric or otherwise better-matched membrane model rather than a mechanistic rejection.

### Step 4 — Calibrate leakage, optical artifacts, and membrane destruction

Use an encapsulated small fluorescent reporter for kinetic screening.

For each protein concentration and relevant buffer condition, include:

- Loaded vesicles without added protein.
- Reporter-free vesicles plus protein.
- Free reporter plus protein.
- Fully disrupted loaded vesicles.
- Dilution standards spanning the assay range.

These controls detect protein fluorescence, scattering, quenching, detector saturation, and changes in the maximum signal.

A suitable kinetic readout is:

\[
D(t)=100\frac{F(t)-F(0)}{F_{\mathrm{complete\ release}}-F(0)}
\]

after appropriate optical blank correction.

**Call this a normalized dequenching index, not automatically the percentage of cargo released.** Partial intravesicular dilution can alter fluorescence without an equivalent fraction of cargo leaving the vesicles.

For selected conditions, independently measure free and vesicle-associated reporter by a calibrated separation method, with:

- Reporter recovery and mass balance.
- Verified vesicle recovery.
- A measured processing-time effect.
- Checks that separation itself does not induce leakage.

A detergent endpoint establishes maximum reporter release; it is **not** a pore-forming positive control.

**Batch acceptance:** reject preparations with excessive spontaneous leakage, unstable endpoint signals, or inadequate dynamic range. Set numerical limits from pilot calibration and freeze them before confirmation. Rejection must depend on these criteria, not on whether gasdermin D appears active.

### Step 5 — Conduct a bounded discovery experiment

A proposed initial screen is:

- Total lipid: approximately 100 µM.
- Protein:lipid molar ratios: approximately 1:10,000, 1:3,000, 1:1,000, 1:300, and 1:100.
- Continuous or closely spaced fluorescence measurements, with prespecified summaries at 5, 15, 30, and 60 minutes.
- At least two independently prepared protein batches and two vesicle preparations.

These are **starting ranges**, not physiological concentrations or known effective doses. Do not extend concentration indefinitely until membranes fail. Record aggregation, insolubility, and gross vesicle destruction throughout.

Compare the complete protein panel. Include an unrelated soluble protein comparator at matched molar concentration, while reporting differences in total protein mass. Full-length and carboxy-terminal proteins are mechanistic comparators, not presumed inert controls.

Discovery goals are to:

1. Identify assay-compatible conditions.
2. Estimate batch variability and dose-response behavior.
3. Identify any reproducible activity below aggregation or gross-destruction limits.
4. Choose a primary formulation and dose for independent confirmation.

Selecting a responsive formulation here is acceptable if selection is disclosed and validation uses new preparations. It does not establish that the formulation is uniquely or physiologically preferred.

### Step 6 — Independently confirm direct membrane activity

**Independent units**

A protein preparation means an independent expression and purification, not another aliquot. A vesicle preparation means an independently assembled and loaded batch, not another well.

A proposed confirmatory starting design is:

- Six independently prepared protein sets.
- Six independently prepared vesicle batches.
- Balanced crossing so each protein preparation is tested with at least two vesicle batches and vice versa.
- Two technical wells per condition and pairing.
- Experiments distributed over at least three days.

This is a proposed minimum design, **not a power calculation**. Use pilot variance to determine whether more independent preparations are required for the prespecified resolution. If resources cannot provide that precision, report the limitation rather than treating nonsignificance as absence of activity.

**Allocation and blinding**

- Randomize well positions and assay order within day.
- Balance treatment groups across plates and positions.
- Use coded protein samples where practical.
- Blind image selection, image scoring, and primary analysis to treatment identity.
- Disclose unavoidable operator unblinding during cleavage or reagent preparation.
- Analyze all quality-qualified batches; document exclusions before decoding where possible.

**Primary endpoint and analysis**

Prespecify one formulation, dose, and time-based endpoint—for example, the 60-minute normalized dequenching index. Specify which contrasts distinguish amino-terminal activity from vehicle, mock purification, caspase carryover, and other protein comparators.

Use a model that accounts for protein preparation, vesicle preparation, and day. Technical wells are subsamples, not independent biological replicates. If the variance structure cannot be estimated reliably, present preparation-level effects and uncertainty rather than inflating sample size with wells.

Report:

- Effect sizes and confidence intervals.
- Individual preparation-level results.
- Dose and time dependence as secondary analyses.
- Multiplicity-adjusted inference for the prespecified control comparisons.

Define a minimum resolvable effect from calibration and independent pilot variation before confirmation. Do not confuse assay detectability with biological importance.

**Direct-activity criterion:** reproducible fragment-dependent leakage exceeding the prespecified resolution, absent comparable activity from contamination controls, with confirmation by the independent cargo measurement.

### Step 7 — Distinguish pores from general membrane destruction

Advance only validated, nonaggregating active conditions to these tests.

#### 7A. Cargo-size dependence

Prepare matched vesicles containing reporters spanning a range of measured hydrodynamic sizes. Use separate preparations where coencapsulation changes loading or membrane stability.

Measure release kinetics and endpoint recovery for each reporter. Control osmotic pressure, reporter–protein interactions, and free-label contamination.

**Prediction:** preferential passage of smaller reporters while larger reporters remain enclosed supports a restricted permeability pathway. However, transient defects can also be size-selective. Molecular mass alone must not be converted into a precise pore diameter.

#### 7B. Electrical permeability

Test the same qualified protein preparations on planar lipid bilayers or another suitable single-membrane electrical system.

- Calibrate electronics using electrical standards.
- Record baseline noise, bilayer capacitance, and stability.
- Apply vehicle, amino-terminal fragment, and matched protein/caspase controls in randomized runs.
- Use voltages that do not destabilize untreated bilayers.
- Prespecify the event-detection threshold from baseline noise.
- Treat independently formed bilayers as assay units; individual current transitions are repeated observations.

Reproducible conductance increases in otherwise intact membranes support aqueous pathways. Discrete transitions strengthen a pore interpretation, but irregular currents do not automatically refute it. Catastrophic failure alone is insufficient.

#### 7C. Structural preservation and protein localization

At matched times and doses, examine:

- Vesicle size and number.
- Intact vesicles versus fragments and collapsed membranes.
- Membrane-associated protein.
- Protein assemblies and membrane-spanning openings using suitable high-resolution imaging.

Use randomized fields, blinded scoring, and an image-selection rule fixed before analysis. Images are subsamples nested within independent preparations.

Measure membrane binding with a separation method that distinguishes lipid-associated protein from free aggregates. If fluorescent labeling is used, verify that labeled protein retains the unlabeled preparation’s activity.

**Interpretation rule:** leakage plus protein binding is not enough to claim pores. Conductive intact membranes, restricted permeability, and structurally localized openings provide convergent evidence. Claiming a **protein-lined** pore requires structural evidence resolving the protein–membrane arrangement, not merely observing rings.

### Step 8 — Resolve negative reconstitution before invoking another executor

If purified fragment does not permeabilize the tested membranes:

1. Recheck sequence, cleavage boundaries, protein recovery, aggregation, tags, and storage.
2. Compare separately expressed and cleavage-generated fragment.
3. Test whether assay buffer or an inactive preparation suppresses an independently active preparation, if one becomes available.
4. Revisit membrane composition, leaflet accessibility, ionic conditions, and observation duration within a bounded, documented extension.
5. Confirm that the cellular benchmark still shows cleavage and fragment-associated cytotoxicity.

If the protein remains negative despite these checks, test cellular add-back.

Use fractions from a gasdermin-D-deficient background, or otherwise verify absence of endogenous gasdermin D activity. Test each fraction:

- Alone.
- With amino-terminal fragment.
- With full-length or carboxy-terminal material.
- After appropriate fractionation or selective component removal.

First identify a reproducible add-back effect; then reduce it to defined components. If protease treatment is used to test protein dependence, remove or inactivate the protease before adding gasdermin D and verify that residual treatment does not damage the assay components.

**Critical limit:** crude-fraction rescue shows that something in the fraction enables activity. It does not identify a separate executor. The factor might supply lipids, modify gasdermin D, promote assembly, or itself injure membranes.

To distinguish these possibilities, test whether gasdermin D remains necessary during membrane injury, whether the factor merely primes gasdermin D, and whether an activated downstream component can injure membranes without gasdermin D.

### Step 9 — Test whether the reconstituted activity explains cellular death

If direct membrane activity is established, develop separation-of-function variants experimentally. No relevant residues are supplied.

Seek a variant that loses reconstituted permeability while retaining, as far as measurable:

- Correct expression and stability.
- Caspase cleavage.
- Comparable soluble recovery.
- Membrane association, if specifically testing assembly rather than binding.

Re-express full-length wild-type and candidate variant in a gasdermin-D-deficient cellular background at matched, controlled abundance. Use a trigger first validated in that model to produce caspase activation and gasdermin D cleavage; the packet does not identify a trigger.

Measure the temporal sequence of:

1. Caspase activation and gasdermin D cleavage.
2. Fragment localization or assembly.
3. Membrane-impermeant tracer entry.
4. Cellular swelling, rupture, and loss of viability.

Include deficient cells, wild-type rescue, matched variant rescue, and unstimulated controls. Randomize imaging order and blind scoring. Independent cultures and independently generated rescue lines—not individual imaged cells—provide biological replication.

Loss of both purified membrane activity and cellular death, despite preserved upstream processing, would strengthen causal linkage. A generally unstable or poorly expressed variant would not.

### Step 10 — Maintain an auditable record

For every experiment retain:

- Reagent identities, batch lineage, and raw quality-control data.
- Allocation maps and blinding codes.
- Protein/lipid concentrations and their measurement methods.
- Raw kinetic traces, uncropped images, electrical recordings, and analysis code.
- All exclusions, failures, protocol changes, and timing deviations.
- A distinction between exploratory and confirmatory results.

Report the tested condition space explicitly so that a negative result has a defined scope.

## 4. Stop rules and troubleshooting

| Problem or observation | Required action |
|---|---|
| Excessive spontaneous leakage or failed optical calibration | Reject the assay batch under the frozen criteria; repair membrane preparation or detection before interpreting protein effects. |
| Caspase, mock purification, or residual additives reproduce the effect | Stop attribution to gasdermin D; improve purification and repeat with independent preparations. |
| Activity appears only with visible aggregation or gross membrane destruction | Do not claim specific pore formation. Lower loading, improve sample quality, and quantify membrane preservation. |
| Inconsistent activity across preparations | Audit identity, cleavage, recovery, storage, contaminants, and lipid variation. Do not retain only active batches. |
| Fluorescence and independently measured cargo release disagree | Treat leakage as unresolved; investigate quenching, adsorption, separation artifacts, and incomplete reporter recovery. |
| Binding without leakage | Consider nonproductive association, missing assembly conditions, or an insensitive readout; binding alone is not execution. |
| Leakage without detectable structural pores | Consider small or transient openings, imaging limitations, or nonspecific disruption. Use electrical and membrane-preservation evidence; retain a narrower conclusion. |
| No activity after the predefined bounded validation effort | Stop broad concentration escalation. Report the negative condition space and move to targeted cofactor or membrane-composition tests. |
| Confirmatory uncertainty remains too wide | Conclude inconclusive, not negative. Any extension must follow a predefined rule rather than stop when significance appears. |

## 5. Conditional conclusions

### Positive: direct permeability with convergent pore evidence

If well-characterized amino-terminal protein permeabilizes protein-free membranes, controls exclude carryover artifacts, and intact-membrane electrical and structural results support openings:

**Strongest justified conclusion:** the fragment is sufficient to produce membrane pores under the defined reconstitution conditions; another cellular protein is not obligatory for that activity in this system.

This does **not** alone establish the physiological target membrane, required cellular lipids, exclusive death mechanism, or that pore formation necessarily causes terminal cellular rupture.

### Positive leakage, but no convincing pore evidence

**Conclusion:** the fragment directly permeabilizes or disrupts lipid membranes under the tested conditions. “Pore-forming” remains unproven. Distinguishing restricted pathways from destructive membrane destabilization becomes the next question.

### Negative purified assay, with defined add-back rescue

**Conclusion:** the identified component is required or strongly enabling under those assay conditions. Whether it is an activator, assembly cofactor, lipid supplier, or executor requires further discrimination.

### Negative purified assay without rescue

**Conclusion:** no direct membrane activity was detected above the calibrated limit in the tested condition space. This does not establish indirect execution or disprove direct action in a different membrane or protein state.

### Cellular separation-of-function agreement

If loss of reconstituted membrane activity tracks loss of death while processing and other relevant properties remain intact:

**Conclusion:** the defined membrane activity is strongly implicated in cellular execution. Residual uncertainty concerns unmeasured effects of the variant and physiological context.

### Ambiguous or discordant results

Preparation-specific activity, activity only at destructive loading, inconsistent reporters, or nonspecific mutant defects prevent a mechanistic assignment.

**Overall decision priority:** first establish artifact-resistant direct membrane sufficiency; then distinguish pores from disruption; finally connect that physical activity to cellular death. This sequence extracts the most mechanistic information from the packet without treating cellular cytotoxicity as proof of a membrane pore.
